530019 Stock Overview Operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Jubilant Pharmova Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Jubilant Pharmova Historical stock prices Current Share Price ₹1,063.05 52 Week High ₹1,309.00 52 Week Low ₹525.90 Beta 1.58 1 Month Change -6.85% 3 Month Change -12.88% 1 Year Change 98.85% 3 Year Change 84.67% 5 Year Change 105.18% Change since IPO 4,657.71%
Recent News & Updates
Now 21% overvalued after recent price rise Nov 02
Second quarter 2025 earnings released: EPS: ₹6.47 (vs ₹3.94 in 2Q 2024) Oct 26
Now 21% overvalued after recent price rise Oct 10
Price target increased by 34% to ₹1,170 Oct 05
Jubilant Pharmova Limited Appoints Tushar Gupta as Chief of Operations Oct 01
Investor sentiment improves as stock rises 25% Sep 13 See more updates
Now 21% overvalued after recent price rise Nov 02
Second quarter 2025 earnings released: EPS: ₹6.47 (vs ₹3.94 in 2Q 2024) Oct 26
Now 21% overvalued after recent price rise Oct 10
Price target increased by 34% to ₹1,170 Oct 05
Jubilant Pharmova Limited Appoints Tushar Gupta as Chief of Operations Oct 01
Investor sentiment improves as stock rises 25% Sep 13
Jubilant Pharmova Limited Declares Dividend for the Financial Year Ended March 31, 2024 Aug 30 Jubilant Pharmova Limited, Annual General Meeting, Aug 30, 2024
Jubilant Pharmova Limited, Annual General Meeting, Aug 30, 2024 Aug 07
Jubilant Pharmova Limited Announces the Resignation of Dr. Saji Thomas as Head-R&D (Api) Aug 03
Investor sentiment improves as stock rises 18% Aug 01
First quarter 2025 earnings released: EPS: ₹30.44 (vs ₹0.40 in 1Q 2024) Jul 22
Jubilant Pharmova Limited to Report Q1, 2025 Results on Jul 19, 2024 Jul 11
Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024 May 30
Full year 2024 earnings released: EPS: ₹4.84 (vs ₹3.83 loss in FY 2023) May 30
Jubilant Pharmova Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 May 29
Third quarter 2024 earnings released: EPS: ₹4.22 (vs ₹0.98 loss in 3Q 2023) Feb 04
Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023 Oct 28
Second quarter 2024 earnings released: EPS: ₹3.94 (vs ₹0.34 in 2Q 2023) Oct 28
Price target decreased by 8.9% to ₹395 Aug 19 Jubilant Pharmova Limited to Report Fiscal Year 2024 Results on May 17, 2024
Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023 Aug 08
First quarter 2024 earnings released: EPS: ₹0.40 (vs ₹2.96 in 1Q 2023) Jul 20
Jubilant Pharmova Limited to Report Fiscal Year 2023 Results on Jul 19, 2023 Jun 27 Jubilant Pharmova Limited Announces Change in Directorate
Full year 2023 earnings released: ₹3.83 loss per share (vs ₹26.01 profit in FY 2022) May 30
Jubilant Pharmova Limited to Report Q4, 2023 Results on May 29, 2023 May 23
Now 21% undervalued after recent price drop Mar 15
Price target decreased by 11% to ₹384 Mar 08
Third quarter 2023 earnings released: ₹0.98 loss per share (vs ₹3.20 profit in 3Q 2022) Feb 05
Jubilant Pharmova Limited to Report Q3, 2023 Results on Feb 03, 2023 Jan 26
Price target decreased to ₹391 Nov 07
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 22
Jubilant Pharmova Limited to Report Q2, 2023 Results on Oct 21, 2022 Oct 14
Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022 Sep 15
Price target decreased to ₹434 Sep 06
Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before October 24, 2022 Sep 04
Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022 Sep 01
Consensus forecasts updated Aug 09
Upcoming dividend of ₹5.00 per share Aug 04
First quarter 2023 earnings released: EPS: ₹2.96 (vs ₹10.09 in 1Q 2022) Aug 03
Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022 Jul 30
Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022 Jul 29
Jubilant Pharmova Limited to Report Q1, 2023 Results on Aug 02, 2022 Jul 28
High number of new directors Jul 13
Price target decreased to ₹507 Jul 12
Jubilant Pharmova Limited Approves Executive and Board Changes Jul 02
Consensus EPS estimates fall by 18% Jun 03
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 29
Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before September 7, 2022 May 28
Now 21% undervalued after recent price drop May 11
Investor sentiment improved over the past week Apr 05
Consensus revenue estimates fall by 11% Feb 11
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Feb 07
Price target decreased to ₹711 Jan 18
Second quarter 2022 earnings released: EPS ₹8.97 (vs ₹14.06 in 2Q 2021) Oct 23
Price target decreased to ₹802 Oct 12
Price target decreased to ₹869 Jul 28
First quarter 2022 earnings released: EPS ₹10.09 (vs ₹5.53 in 1Q 2021) Jul 24
Jubilant Pharmova Announces That the US FDA Has Placed Roorkee Facility Under Import Alert Jul 16
Consensus revenue estimates fall to ₹65.7b Jun 11
Full year 2021 earnings released: EPS ₹36.05 (vs ₹56.40 in FY 2020) Jun 06
New 90-day low: ₹752 Mar 08
Price target raised to ₹1,021 Feb 12
Analysts update estimates Feb 12
President of Manufacturing & Whole-Time Director Anant Pande has left the company Feb 08
CEO of Life Science Ingredients & Whole-Time Director Rajesh Srivastava has left the company Feb 08
Jubilant Pharmova Limited Announces Directorate Changes Feb 06
Third quarter 2021 earnings released: EPS ₹13.75 (vs ₹12.77 in 3Q 2020) Feb 06
Earnings beat expectations, revenue disappoints Feb 06
New 90-day high: ₹1,026 Feb 03
Jubilant Life Sciences Limited to Report Q3, 2021 Results on Feb 05, 2021 Jan 29
New 90-day high: ₹978 Jan 13
New 90-day high: ₹866 Dec 24
Market bids up stock over the past week Dec 07
New 90-day high: ₹820 Dec 06
New 90-day low: ₹683 Nov 10
Revenue and earnings miss expectations Nov 06
Second quarter 2021 earnings released: EPS ₹14.06 Nov 06
Jubilant Life Sciences Limited to Report Q2, 2021 Results on Nov 04, 2020 Oct 29
Independent Non-Executive Director recently bought ₹1.1m worth of stock Sep 21
Analysts lower EPS estimates to ₹55.56 Sep 11
Price target raised to ₹725 Sep 07
First quarter earnings released Sep 07
Full year earnings released - EPS ₹56.39 Aug 21
Jubilant Life Sciences Limited to Report Q1, 2021 Results on Sep 04, 2020 Aug 15
New 90-day high - ₹772 Jul 29
Price target raised to ₹638 Jul 16 Shareholder Returns 530019 IN Pharmaceuticals IN Market 7D -4.8% 0.8% -4.2% 1Y 98.8% 39.7% 19.1%
See full shareholder returns
Return vs Market: 530019 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility Is 530019's price volatile compared to industry and market? 530019 volatility 530019 Average Weekly Movement 6.1% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 530019 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 530019's weekly volatility (6%) has been stable over the past year.
About the Company Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.
Show more Jubilant Pharmova Limited Fundamentals Summary How do Jubilant Pharmova's earnings and revenue compare to its market cap? 530019 fundamental statistics Market cap ₹168.33b Earnings (TTM ) ₹5.93b Revenue (TTM ) ₹69.20b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 530019 income statement (TTM ) Revenue ₹69.20b Cost of Revenue ₹23.90b Gross Profit ₹45.29b Other Expenses ₹39.36b Earnings ₹5.93b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
Earnings per share (EPS) 37.45 Gross Margin 65.46% Net Profit Margin 8.57% Debt/Equity Ratio 47.7%
How did 530019 perform over the long term?
See historical performance and comparison Dividends
0.5% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 08:17 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Jubilant Pharmova Limited is covered by 31 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Harith Ahamed Avendus Spark Deepak Khetan Axis Capital Limited Gaurav Chugh Batlivala & Karani Securities India Pvt. Ltd.
Show 28 more analysts 
